Shumao Ni

Shumao Ni

Auto-generated profile, based on publicly available information

Shumao Ni

TransThera Sciences (Nanjing), Inc., Nanjing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Triple-negative breast cancer (TNBC) is a highly heterogeneous cancer lacking actionable targets. Using a phenotypic screen of TNBC cells, we discovered a novel multiple kinase inhibitor tinengotinib (TT-00420) that strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical assays. Exposure to tinengotinib specifically inhibited proliferation across all subtypes of TNBC in vitro and in vivo, while leaving luminal breast cancer cells intact. Incubation of HCC1806 with tinengotinib led to dose-dependent downregulation of genes essential for TNBC cell growth and proliferation. Studies revealed that the potential mechanism of action of tinengotinib involved, predominantly, inhibition of Aurora A or B kinase activity, while inhibition of other pathways contributed to suppression of potency and activity. In vitro treatment of TNBC cell lines or in vivo administration in a syngeneic model with tinengotinib resulted in up-regulation of CXCL10 and 11 or diminished tumor-associated macrophage (TAM) infiltration. Tinengotinib represents a novel combinatorial inhibitory mechanism to treat TNBC. The phase I trial of tinengotinib was completed (ClinicalTrials.gov identifier: NCT03654547).

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.

2 November 2026
Verified
Other
Open access
SPSarina Anne Piha-Paul
Sarina Anne Piha-Paul
CLChih-Yi Liao
Chih-Yi Liao
FDFarshid Dayyani
Farshid Dayyani
NGNashat Y. Gabrail
Nashat Y. Gabrail
SKSyed Kazmi
Syed Kazmi
SGSANJAY GOEL
SANJAY GOEL
PK parameters of once-daily doses during the run-in period and once-daily and twice-daily doses during cycle 1, day 15 in arm C.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib highly inhibits TNBC cell by a panel of specific mechanisms.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
72h-treament of tinengotinib strongly inhibits HUVEC cell viability in a dose-dependent manner.

3 April 2023
Verified
Other
Open access
PPPeng Peng
Peng Peng
XQXiaoyan Qiang
Xiaoyan Qiang
GLGuoyu Li
Guoyu Li
LLLin Li
Lin Li
SNShumao Ni
Shumao Ni
FWFrank Wu
Frank Wu
Tinengotinib indirectly blocks EGFR signaling pathway without affecting PTPN12.